Watson Launches Generic Xopenex

Loading...
Loading...
Watson Pharmaceuticals, Inc.
WPI
today announced that it has launched an authorized generic version of Xopenex (levalbuterol HCl) Inhalation Solution as part of an agreement with Sunovion Pharmaceuticals, Inc. Watson began shipping the product today. Xopenex Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Posted In: NewsEvents
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...